Raybow USA Inc.
Brevard, NC
- UEI
- U8MZCKKS12M3
- CAGE
- 614K8
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 158 McLean Rd, Brevard, NC 28712, USA
- Website
- raybow.com
- Founded
- 2008
- Employees
- 251-1K
- Estimated annual revenue
- $50M-$100M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | $58,000 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Raybow-antiviral compounds (lamivudine) | CDC Pittsburgh | $58,000 | |
| INI-heptanoic acid and DES-methyl-INI-heptanoic acid NLT 95% (hplc) | CDC Pittsburgh | $29,000 | |
| INJ heptanoic acid | CDC Pittsburgh | $45,300 | |
| Procure synthesized chemicals for method development (IAA w/FDA) | Bureau of the Fiscal Service | $38,200 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Dksh (Thailand) Co LTD | Krung Thep Maha Nakhon | 541614 Process, Physical Distribution, and Logistics Consulting Services |
| Sino Biological US Inc. | Paoli, PA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Proteos Inc. | Kalamazoo, MI | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Cambrex | Durham, NC | 325411 Medicinal and Botanical Manufacturing |
| Imquest Biosciences, Inc. | Frederick, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Raybow USA Inc. is a foreign-owned, for-profit corporate entity registered to receive federal awards from the U.S. government. It is a global Contract Development and Manufacturing Organization specializing in small molecule drug development, with offices and facilities in Europe, North America, and China.
Raybow USA Inc. has provided various chemical compounds and substances to the Department of Health and Human Services Centers for Disease Control and Prevention (HHS-CDC) through firm fixed price purchase orders. In August 2023, it was awarded a $58,000 contract to deliver Raybow-Antiviral Compounds (Lamivudine) to support the CDC's efforts in providing antiviral medications and preventing infectious diseases. Previously, in June 2021, Raybow USA Inc. received a $29,000 award for supplying INI-HEPTANOIC ACID and DES-METHYL-INI-HEPTANOIC ACID NLT 95% (HPLC) compounds to the CDC. Another contract in July 2020 worth $45,300 involved delivering INJ HEPTANOIC ACID to the same agency. None of these contracts had any set-aside designations or indicated the use of subcontractors. Raybow USA Inc. appears to specialize in providing chemical compounds and substances related to pharmaceutical and antiviral research to federal agencies like the CDC.
Quick answers
Is Raybow USA Inc. registered in SAM.gov?
Yes. Raybow USA Inc.'s SAM.gov registration is active through January 13, 2027.
How much has Raybow USA Inc. received in federal contracts?
Federal contracts obligated $58,000 to Raybow USA Inc. in fiscal years 2023 through 2027.
What is Raybow USA Inc.'s most recent federal award?
Raybow USA Inc.'s most recent federal contract award is Raybow-antiviral compounds (lamivudine) (75D30123P17063), from CDC Pittsburgh, on August 31, 2023.
On GovTribe
See Raybow USA Inc.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors